Sickle Cell Disease Clinical Trials

92 studies are recruiting for sickle cell disease in the United States right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

By city

Studies now recruiting

1. Dietary Intake and Dietary Behaviors in Adults With Sickle Cell Disease

   Background: Sickle Cell Disease (SCD) causes blood cells form a crescent shape. It is caused by a genetic mutation in the hemoglobin gene. People with SCD are at increased risk for illnesses like stroke, chronic pain, and heart problems, as well as decreased overall health and well-being. Researche…

   Stage

   Not phased

   Ages

   18 to 120

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institutes of Health Clinical Center (CC)

   See if you can join NCT05170412 on ClinicalTrials.gov

2. A Research Study Looking at Long-term Treatment With Etavopivat in People With Sickle Cell Disease or Thalassaemia

   Etavopivat is a new medicine under development for treating blood disorders like sickle cell disease and thalassaemia. Sickle cell disease and thalassaemia are inherited blood disorders that affect haemoglobin. Haemoglobin is the protein that carries oxygen through the body. This study is looking i…

   Stage

   Phase 3

   Ages

   2 and older

   Site

   Children's Hospital Los Angeles - Endocrinology, Los Angeles, California

   Locations

   107 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT06609226 on ClinicalTrials.gov

3. Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease

   Background: Sickle cell disease (SCD) is a genetic disease that causes the body to produce abnormal ( sickled ) red blood cells. SCD can cause anemia and life-threatening complications in the lungs, heart, kidney, and nerves. People with SCD are also at increased risk of forming blood clots in the …

   Stage

   Phase 1

   Ages

   18 to 65

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Heart, Lung, and Blood Institute (NHLBI)

   See if you can join NCT05904093 on ClinicalTrials.gov

4. A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease

   This study is conducted to confirm whether etavopivat works well at reducing the number of Vaso-occlusive crisis VOCs (sickle cell pain crises) caused by obstructions in blood vessels in adults and adolescents living with sickle cell disease. The study will also evaluate how well etavopivat can red…

   Stage

   Phase 3

   Ages

   12 and older

   Site

   Uni of Alabama at Birmingham, Birmingham, Alabama

   Locations

   175 in total

   Run by

   Novo Nordisk A/S

   See if you can join NCT06612268 on ClinicalTrials.gov

5. Blood Sampling for Research Related to Sickle Cell Disease

   This study will collect representative blood samples from healthy children and adults and from children and adults who have unique red blood cell features that are related to sickle cell disease. Sickle cell disease is a blood disease that limits the ability of red blood cells to carry oxygen throu…

   Stage

   Not phased

   Ages

   18 to 100

   Site

   National Institutes of Health Clinical Center, Bethesda, Maryland

   Run by

   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

   See if you can join NCT00542230 on ClinicalTrials.gov

6. A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)

   This is an open-label, multicenter, within-participant dose-escalation study examining up to 3 dose levels of DISC-3405 and will assess the safety, tolerability, PK, and PD of DISC 3405 in participants with sickle cell disease.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   University of Alabama at Birmingham, Birmingham, Alabama

   Locations

   9 in total

   Run by

   Disc Medicine, Inc

   See if you can join NCT07187973 on ClinicalTrials.gov

7. Tocilizumab for Acute Chest Syndrome

   The investigators are evaluating the role of a low dose of tocilizumab in treating acute chest syndrome in patients with sickle cell disease. Tocilizumab inhibits interleukin-6 (IL-6) receptors and is used to treat rheumatoid arthritis and severe cytokine release syndrome, which can be seen with ch…

   Stage

   Phase 2

   Ages

   12 and older

   Site

   University of Chicago, Chicago, Illinois

   Run by

   University of Chicago

   See if you can join NCT05640271 on ClinicalTrials.gov

8. A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)

   A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.

   Stage

   Phase 3

   Ages

   12 to 100

   Site

   University Of Alabama, Birmingham, Alabama

   Locations

   35 in total

   Run by

   Novartis Pharmaceuticals

   See if you can join NCT06439082 on ClinicalTrials.gov

9. Sickle Cell Disease Biofluid Chip Technology (SCD BioChip)

   'Sickle-shaped' anemia was first clinically described in the US in 1910, and the mutated heritable sickle hemoglobin molecule was identified in 1949. The pathophysiology of SCD is a consequence of abnormal polymerization of sickle hemoglobin (HbS) and its effects on red cell membrane properties, sh…

   Stage

   Not phased

   Ages

   12 and older

   Site

   University Hospitals Case Medical Center, Cleveland, Ohio

   Run by

   University Hospitals Cleveland Medical Center

   See if you can join NCT02824471 on ClinicalTrials.gov

10. Study to Understand the Genetic Risk of Developing an Immune Response After Blood Transfusions Among Individuals With Sickle Cell Disease

    The purpose of this research study is to look at genes and determine how they interact with each other to find changes that could explain why some people's immune systems may respond to blood transfusions. This response is called an alloimmune response. We strongly believe that when someone has an …

    Stage

    Not phased

    Ages

    2 to 99

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Human Genome Research Institute (NHGRI)

    See if you can join NCT06944067 on ClinicalTrials.gov

11. Assessing Molecular Mechanisms and Effects of Music Therapy in Youth With Sickle Cell Disease Using Single-cell RNA-sequencing

    The goal of this clinical trial is to evaluate whether a 4-week music therapy (MT) intervention can reduce chronic pain and improve psychosocial outcomes in youth with sickle cell disease (SCD). The main questions it aims to answer are: * Does MT reduce pain intensity, frequency of pain episodes, a…

    Stage

    Not phased

    Ages

    8 to 18

    Site

    Children's Healthcare of Atlanta, Atlanta, Georgia

    Run by

    Emory University

    See if you can join NCT07562451 on ClinicalTrials.gov

12. A Phase I/II Study of ITU512 in Healthy Participants and Patients With Sickle Cell Disease

    The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary food effect of ITU512 as well as the fetal hemoglobin (HbF)-inducing capacity of ITU512. This will be the first evaluation of the potential therapeutic effect of ITU512 in healthy participants …

    Stage

    Phase 1

    Ages

    12 to 55

    Site

    University of Alabama Birmingham, Birmingham, Alabama

    Locations

    10 in total

    Run by

    Novartis Pharmaceuticals

    See if you can join NCT06546670 on ClinicalTrials.gov

13. Early Screening and Treatment of Heart Complication in Sickle Cell Disease

    This study tests whether early heart screening and treatment for iron overload in subjects with sickle cell disease can prevent heart problems and reduce hospitalizations.

    Stage

    Phase 2

    Ages

    18 and older

    Site

    Inova Schar Cancer, Fairfax, Virginia

    Locations

    2 in total

    Run by

    Inova Health Care Services

    See if you can join NCT07023666 on ClinicalTrials.gov

14. Methylphenidate to Address Attention and Executive Deficits Among Children With Sickle Cell Disease

    The purpose of this study is to determine if patients with sickle cell disease (SCD) can consistently take a drug called Methylphenidate (MPH) daily, once a day for 4 weeks to help with any thinking, attention or schoolwork problems and if they have any side effects. The study will assess any think…

    Stage

    Phase 1

    Ages

    8 to 17

    Site

    St. Jude Children's Research Hospital, Memphis, Tennessee

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT07226219 on ClinicalTrials.gov

15. Collection of Human Biospecimens for Basic and Clinical Research Into Globin Variants

    Background: Blood disorders like sickle cell disease and malaria affect many people around the world. Researchers want to learn more about blood disorders. To do this, they need to collect biological samples from people with blood disorders. They also need to collect samples from healthy people. Ob…

    Stage

    Not phased

    Ages

    18 to 70

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Institute of Allergy and Infectious Diseases (NIAID)

    See if you can join NCT03937817 on ClinicalTrials.gov

16. SCD Stem Cell Mobilization and Apheresis Using Motixafortide

    This study is being done to see if the study drug, motixafortide, is safe in participants with sickle cell disease (SCD). Investigators also want to see if the drug will help the body increase the number of stem cells that can be collected for possible future transplant use. PRIMARY OBJECTIVE * To …

    Stage

    Phase 1

    Ages

    18 and older

    Site

    University of Alabama at Birmingham, Birmingham, Alabama

    Locations

    3 in total

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT06442761 on ClinicalTrials.gov

17. Partial Stem Cell Transplant for Sickle Cell Disease From Matched Donors

    This is a non-ablative (partial) stem cell transplant for patients with severe sickle cell disease or beta-thalassemia requiring red cell transfusions. The intensity of the transplant is slightly increased from our previous transplant regimens. The goal is to aim for higher percentage of donor cell…

    Stage

    Phase 1

    Ages

    4 to 65

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Heart, Lung, and Blood Institute (NHLBI)

    See if you can join NCT07599176 on ClinicalTrials.gov

18. Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults

    The purpose of this research is to see if ketamine is effective and safe in treating children and young adults with sickle cell disease experiencing sickle cell related pain. In this study, we will compare the outcomes (such as pain scores) in persons who receive standard of care pain medicine (an …

    Stage

    Phase 2

    Ages

    5 to 20

    Site

    Harbor UCLA Medical Center, Torrance, California

    Run by

    Mohsen Saidinejad

    See if you can join NCT07369024 on ClinicalTrials.gov

19. Determination of Red Cell Survival in Sickle Cell Disease and Other Hemoglobinopathies Using Biotin Labeling

    Background: Sickle cell disease (SCD) is an inherited disorder of the blood. SCD causes red blood cells (RBCs) to die early. This can lead to a shortage of healthy cells. SCD and other blood disorders can be managed with drugs or cured with a bone marrow transplant. Researchers want to know how lon…

    Stage

    EARLY_Phase 1

    Ages

    18 to 100

    Site

    National Institutes of Health Clinical Center, Bethesda, Maryland

    Run by

    National Heart, Lung, and Blood Institute (NHLBI)

    See if you can join NCT06313398 on ClinicalTrials.gov

20. Cerebrovascular Reactivity Measurements With High-Density Diffuse Optical Tomography

    The purpose of the study protocol is to identify imaging biomarkers for brain tissue under high metabolic stress at risk for permanent injury. We will measure oxygen extraction fraction (OEF) and cerebrovascular reactivity (CVR) in participants with and without perturbations in cerebral oxygen deli…

    Stage

    Not phased

    Ages

    6 to 70

    Site

    Washington University in St. Louis, St Louis, Missouri

    Run by

    Washington University School of Medicine

    See if you can join NCT07776444 on ClinicalTrials.gov

21. A Phase 2/3 Study of Osivelotor in Adult and Adolescent Participants With SCD

    The purpose of this study is to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of osivelotor.

    Stage

    Phase 2

    Ages

    12 and older

    Site

    AMR Clinical, Mobile, Alabama

    Locations

    80 in total

    Run by

    Pfizer

    See if you can join NCT05431088 on ClinicalTrials.gov

22. ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders

    In parallel with the growth of ATHN's clinical studies, the number of new therapies for all blood disorders is increasing significantly. Some of the recently FDA-approved therapies for congenital and acquired hematologic conditions have not yet demonstrated long-term safety and effectiveness beyond…

    Stage

    Not phased

    Ages

    Any age

    Site

    Arizona Hemophilia and Thrombosis Treatment Center at Phoenix Children's Hospital, Phoenix, Arizona

    Locations

    76 in total

    Run by

    American Thrombosis and Hemostasis Network

    See if you can join NCT04398628 on ClinicalTrials.gov

23. Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0

    The proposed research is to determine the clinical efficacy and neurobiological mechanisms of acupuncture analgesia in patients with sickle cell disease.

    Stage

    Not phased

    Ages

    14 to 80

    Site

    University of Cincinnati College of Medicine, Cincinnati, Ohio

    Run by

    University of Cincinnati

    See if you can join NCT06725550 on ClinicalTrials.gov

24. Gene Therapy Communication: Use of a Needs Assessment to Drive Decision-AIDS for Gene Therapy for Rare Diseases (GENETX)

    This prospective mixed-method interview study aims to qualitatively describe the beliefs, attitudes, and informational needs around gene therapy for rare pediatric diseases among patients and parents of children with a rare disease targeted for treatment using gene therapy techniques. Using learned…

    Stage

    Not phased

    Ages

    8 and older

    Site

    St. Jude Children's Research Hospital, Memphis, Tennessee

    Run by

    St. Jude Children's Research Hospital

    See if you can join NCT05810181 on ClinicalTrials.gov

25. Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)

    This is a phase 2a, global, multicenter, randomized, double-blind, placebo-controlled study investigating the safety of anumigilimab administered subcutaneously (SC) at the maximum tolerated dose (MTD) in adult participants with SCD. The primary aim of the study is to assess the safety of anumigili…

    Stage

    Phase 2

    Ages

    18 and older

    Site

    UAMS Medical Center, Little Rock, Arkansas

    Locations

    16 in total

    Run by

    CSL Behring

    See if you can join NCT07224360 on ClinicalTrials.gov